Management Team

  Our Team


|Zhenhua Huang, Ph.D, Founder, Executive Chairman

As the chief executive of the company, Zhenhua oversees the strategic direction of KBP. He is fully engaged in all aspects of KBP’s operations.

Zhenhua is a serial entrepreneur. He started the first venture in 1998. In 2008, his venture, Xuan Zhu Biosciences, was acquired by publicly listed Sihuan Pharma (HK 0460). The pipeline he built at Xuan Zhu Biosciences still drives the sales of Sihuan. In his current position as KBP’s Executive Chairman, Zhenhua has dedicated himself to new molecular entity R&D. Under his leadership, KBP has built a strong pipeline for the global market, with multiple compounds in the clinics.

Zhenhua obtained his Ph.D in pharmacology from Shenyang Pharmacology University, and EMBA from Peking University.

|Fred Yang, Ph.D, Chief Development Officer

Fred leads development of medical strategies of the company. In this capacity Fred provides leadership and insights of medical development of the company’s clinical stage compounds.

Fred has almost 20 years of experience in clinical research and drug development, with expertise focusing on statistics and quantitative science. He assumed increasing responsibilities in both Big Pharma (Abbott, Pharmacia, GSK etc.) and small biotech (Discovery Labs), overseeing biostatistics as well as trial conduct and strategic planning. He had successful end-to-end development and worldwide regulatory experiences. His therapeutic experiences range from diabetes, CV, arthritis, oncology and neonatal care, with many publications.

Fred is currently adjunct associate professor at Drexel University Medical School. He is also a consultant for International Breast Cancer Research Foundation (IBCRF).

Fred received his undergraduate education at Peking University and his Ph.D degree from University of Wisconsin.

|Robert Segal, MD, Deputy Chief Medical Officer

Robert Segal has over 25 years of medical and pharmaceutical/biotech experience in senior executive positions with Fortune 20 and biotech companies. He previously served as Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer of Discovery Laboratories, Inc. Prior to joining the Discovery Labs, he held the position of Director, Cardiovascular Clinical Research at Merck Research Laboratories, having joined Merck & Co, Inc. in 1992 as Associate Director. Dr. Segal received his medical degree from the University of Pretoria Medical School, South Africa. Dr. Segal is a diplomat of the American Board of Internal Medicine with sub-specialty certification in nephrology and is a Fellow of the American College of Physicians.  He completed his internship and residency in medicine at Sinai Hospital, Baltimore, and clinical postdoctoral fellowships in general medicine at The Johns Hopkins Hospital and nephrology/transplant medicine at UCLA, as well as a research fellowship in molecular biology at UCLA.  Prior to joining Merck, he was an Assistant Professor of Medicine in the Division of Nephrology at UCLA School of Medicine and served as an intern advisor to the Biotechnology Program at Northwestern University. Dr. Segal has over $10M in NIH funding with a focus on development of biodefense medical countermeasures.

|Vincent J. Benn, Ph.D, MBA, Vice President, Regulatory & Medical Affairs

Vince brings more than 30 years of clinical and regulatory drug and biologics development experience to KBP BioSciences. Previously, he was Vice President Clinical & Regulatory Affairs at Essential Pharmaceuticals, Vice President Worldwide Clinical Operations at Discovery Labs, and Global Clinical Program Director at Aventis Behring LLC.  Previous clinical research projects span wide range of therapeutic areas, such as immunology, allergy, asthma, rheumatoid arthritis, and cardiology in several pharmaceutical companies including Pharmacia, Ortho, Rhone-Poulenc Rorer, and Merck. He has developed and defended clinical development plans before FDA, EMEA, MCA, MPA, and the Paul Erlich Institute (PEI).

He received his A.B. in Biological Science and English, M.S. in Physiology and Zoology, and Ph.D in Immunology from Rutgers University. He received additional training in clinical immunology at Harvard Medical School and The University of Texas.  He completed his M.B.A at the Fox School of Management at Temple University.  In addition, he was Regulatory Affairs Certified (R.A.C.) by the Regulatory Affairs Professional Society.

|Paul Chow, Ph.D, DABT, Vice President, Pharmacology & Toxicology


Over his 35-year career in the drug industry, Dr. Chow has been involved in the development of several exciting new medicines. He played key roles in the successful submission of 6 NDA’s and prepared over 30 IND’s. As VP of Pharmacology & Toxicology, Paul helps shape directions of KBP’s pipeline strategy.

Paul’s productive career includes Pharma (Wyeth, Purdue), Biotech (Genentech) and startup companies (TaiGen). His hands-on experiences encompasses discovery research, preclinical/clinical phases to product registration in multiple therapeutic areas, ie, cardiovascular, neuropharmacology, anti-infective and oncology.

Paul obtained his BS (Chemistry), MS (Environmental Health), and PhD (Pharmacology and Toxicology) from University of Michigan. Dr. Chow has been a Member of the Society of Toxicology and certified by the American Board of Toxicology since 1981.

Advisory Board


|Bertram (Bert) Pitt, MD

Bertram (Bert) Pitt, MD

Professor Emeritus, University of Michigan Medical School

Dr. Pitt’s research is in cardiovascular disease, with special emphasis on the ischemic heart disease and heart failure. He spent 15 years as the Director, Division of Cardiology at University of Michigan School of Medicine. Dr. Pitt has chaired or co-chaired a number of clinical trials in cardiology including SOLVD; ELITE I and II; PREVENT; RALES; EPHESUS; and TOPCAT and has published over 500 articles in peer reviewed journals.  Dr. Pitt has been a member of a numerous medical journal editorial boards and medical organizations, as well as served as an advisor to the clinical trials branch of the NHLBI and a member of the FDA cardio-renal advisory board.  He has been awarded the James B. Herrick Award by the Council of Clinical Cardiology of the American Heart Association. He is Diplomate of the American Board of Internal Medicine and of the American Board of Cardiology.

Dr. Pitt is a member of numerous professional societies and has held office in several of them. Among others, he was Chairman, Council on Circulation of the American Heart Association, Chairman, Young Investigator’s Award Committee of the American College of Cardiology, and is currently Chairman of the Reveal Committee of the ACC.

Dr. Pitt received his MD degree from the University of Basel, Switzerland.  He completed fellowship in cardiology at the Johns Hopkins University School of Medicine.

|George Bakris, MD, FASN, FAHA, FASH

Professor of Medicine, University of Chicago

Dr. Bakris conducts research related to hypertension, diabetes, and renal disease, and participates in clinical trials investigating the progression of diabetic renal disease and the effects of antihypertensive medications on renal disease progression. He was a principal investigator for several influential clinical trials, including AASK, GEMINI, GUARD, among many others. Dr. Bakris has served on the executive committees of multiple national reports and guidelines, including JNC VI, 1997, JNC 7, 2003, ISHIB (2003), NKF K/DOQI, and the American Diabetes Association Practice Guideline Committee (2002-2004).

Dr. Bakris is a member of numerous national committees and professional societies, and serves on many of their advisory boards, including those of the American Diabetes Association, American Society of Nephrology, the ISHIB, and the NKF. He is Past President of the American College of Clinical Pharmacology. Dr. Bakris currently serves on 14 editorial boards, including those of the American Journal of Hypertension, American Journal of Nephrology, Hypertension, and the Journal of Clinical Pharmacology and Ethnicity & Disease. His research has been published in more than 200 articles.

Dr. Bakris obtained his medical training at the Rosalind Franklin University of Medicine and Science and completed is residency training at the Mayo Clinic.

|John McMurray, MD

John McMurray, MD

Professor of Medical Cardiology, University of Glasgow

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular (CV) Disease at the Brigham and Women’s Hospital, Boston, USA, and visiting Professor of Medicine, Harvard University, Boston, in 2010/2011. He is also Past-President of the Heart Failure Association of the European Society of Cardiology (ESC).

Professor McMurray’s primary research interest is in heart failure (HF) and his main research activity is clinical trials. He is, or was, the principal investigator, and member of the executive committee or steering committee in a number of large trials in HF, other CV diseases, renal disease and diabetes.

Professor McMurray sits on the editorial board of the New England Journal of Medicine. He has published approximately 600 original papers, reviews, and book chapters and was the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition he was Co-Chair of the Kidney Disease Improving Global Outcomes Anemia Guidelines Committee; and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee. He is a member of the National Institute for Health and Care Excellence (NICE) Acute HF Guidelines Committee and was recently appointed to NICE (Appraisal Committee A). Professor McMurray was included in the 2014 listing of Highly Cited Researchers by Thomson-Reuters.

|Faiez Zannad, MD, Ph.D

Faiez Zannad, MD, Ph.D

 Center of Clinical Investigation, CIC, Inserm and University of Lorraine, CHU de Nancy, Nancy, France

 Faiez Zannad is Professor of Therapeutics at the University of Lorraine in Nancy, France. He earned his MD degree and cardiology specialty at the University of Lorraine in 1979 and his Ph.D degree in clinical pharmacology at the University of Lyon in Lyon, France, in 1984; during his Ph.D study, he also completed a fellowship at the MRC Clinical Pharmacology unit, Oxford, UK. Professor Zannad is currently Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux” in the Centre Hospitalier et Universitaire of Nancy.

Professor Zannad coordinates two EU FP7 grants in heart failure: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response [www.homage‐hf.eu]) and FIBROTARGETS (fibrosis as a biotargets [www.fibrotargets.eu]). As the primary investigator or member of the oversight committees in major clinical trials, Professor Zannad has made significant contributions to evidence‐based heart failure life‐saving therapy, mainly with beta‐blockers (CIBIS) and mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS‐HF). He pioneered cardiovascular outcome trials in chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST) and the one of the first cardiovascular safety trials on glucose‐lowering drugs in diabetes (EXAMINE). Professor Zannad has served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He was Founder and

is currently Chairman of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international meeting dedicated to the science of clinical trials, and of the International Workshop on Biomarkers in heart failure. As of July 2016, Professor Zannad has authored more than 530 scientific publications.

|Richard G. Wunderink, MD

Richard G. Wunderink, MD

Northwestern University Feinberg School of Medicine

Richard Wunderink is a Professor of Medicine in the Pulmonary and Critical Care Division of Northwestern University Feinberg School of Medicine and Medical Director of the MICU, Northwestern Memorial Hospital. Dr Wunderink has been active in research and education regarding on pulmonary infections, especially community-acquired pneumonia and ventilator-associated pneumonia, and sepsis. His research interests include prevention, diagnosis, risk stratification, and treatment, both antibiotic and adjunctive therapies, for these serious infectious diseases. He co-chaired the most recent IDSA/ATS Consensus Guidelines Committee on the management of community-acquired pneumonia. He was a member of the last American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) committee which developed guideline statements on hospital-acquired and healthcare-associated pneumonia and currently serves on the ERS/ ESCIM/ ESCMID/ ALAT Guidelines for the management of Hospital acquired pneumonia.

|Frédéric Jaisser, MD, Ph.D

Frédéric Jaisser, MD, Ph.D

Head of Integrative Physiology and Pathophysiology Department, Cordeliers Research Centre, France

Dr. Jaisser joined the National Institute of Health and Medical Research (INSERM) in 1996 as Director of Research.  In 2003, he joined the Collège de France in Paris as an independent INSERM team and is currently the director of a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. Between 2010-2015, he was Scientific Delegate of the Pathophysiology Committee of the French National Research Agency. He has been recently appointed as French coordinator for Live Sciences in the ECOS French-South America exchange program.

The aim of his current studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system. His work combines cellular and molecular approaches, animal physiology, pharmacological studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of mineralocorticoid receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists. He published 100 papers (H index 33, 2800 citations). Dr. Jaisser received his medical training and degrees from the Reims Medical School and was qualified as Nephrologist in 1990.

|Al Gianchetti, MBA

Al Gianchetti, MBA

Drug Development and Commercialization Strategy Advisor

Al Gianchetti is President and CEO of Longview Biopharm Partners.  He has over 25 years of experience in biopharmaceuticals in both R&D and US and global operations, including 7 years in the biotech environment and the remainder at GSK.  In VP, Chief Commercial Officer and in other leadership positions, he has sat on governance boards in sales, brand management, payer and managed care, drug discovery, drug development, business and corporate development and supply chain allowing him a broad view of the business.

Al was involved in development of 7 phase III programs and more than 10 phase I/II programs, led several US and global product launches and the acquisition/licensing of more than 10 products.  His therapeutic experience includes infectious diseases, psychiatry and neurosciences, cardio-metabolic-renal diseases including diabetes, oncology and urologic/men’s health.

|Clare Kahn, Ph.D

Clare Kahn, Ph.D

Independent Adviser

Dr. Kahn has over 30 years of experience in the pharmaceutical industry with a proven leadership record in drug development, registration and life-cycle. She has held senior roles growing high functioning teams in research and development, regulatory strategy and business development at the portfolio level encompassing small molecules, biologicals and vaccines.

Dr. Kahn joined Pfizer in 2010 where she served as Vice President and Head of Global Regulatory Affairs for the $16bn Specialty Care Portfolio before expanding her responsibilities to lead the Global Innovative Pharma Portfolio in 2014. In these roles she drove Pfizer’s global regulatory development for vaccines, anti-infectives, inflammation, rare disease, neuroscience, pain, ophthalmology, cardiovascular, metabolic, renal and gender health.

Dr. Kahn joined Pfizer from GlaxoSmithKline (GSK) where she served in preclinical and clinical disposition and metabolism moving into international regulatory affairs and business development. She served in a series of Vice Presidential roles and supported a wide range of therapeutic areas at GSK including pulmonary, anti-infectives, oncology, cardiovascular, metabolic, urology with eleven years in vaccine development.

Dr. Kahn has a Ph.D in Biochemical Pharmacology from the Department of Clinical Pharmacology at The Royal Postgraduate Medical School, London and moved to Philadelphia to serve as Assistant Professor in the Departments of Pharmacology and Laboratory Medicine at the University of Pennsylvania. Dr. Kahn served on the Executive Committee of the Graduate Group in Pharmacological Sciences and retained an adjunct faculty position for several years after joining industry.